(5-((4-(4-Chlorophenyl)piperidin-1-yl)sulfonyl)picolinoyl)glycine

Catalog No. :
ACZXFN647
CAS No. :
2851040-81-6
Molecular Formula :
C19H20ClN3O5S
Molecular Weight :
437.90

IUPAC Name:(5-((4-(4-chlorophenyl)piperidin-1-yl)sulfonyl)picolinoyl)glycine

(5-((4-(4-Chlorophenyl)piperidin-1-yl)sulfonyl)picolinoyl)glycine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg98%$73.00Login to see priceIn stockInquiry
10mg98%$109.00Login to see priceIn stockInquiry
25mg98%$216.00Login to see priceIn stockInquiry
50mg98%$366.00Login to see priceIn stockInquiry
100mg98%$623.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(5-((4-(4-Chlorophenyl)piperidin-1-yl)sulfonyl)picolinoyl)glycine
IUPAC Name(5-((4-(4-chlorophenyl)piperidin-1-yl)sulfonyl)picolinoyl)glycine
Molecular FormulaC19H20ClN3O5S
Molecular Weight437.90
SMILESO=C(O)CNC(C1=NC=C(S(=O)(N2CCC(C3=CC=C(Cl)C=C3)CC2)=O)C=C1)=O
InChI KeyHIWYRXWPCQHOSO-UHFFFAOYSA-N
SynonymUSP5-IN-1;(5-((4-(4-Chlorophenyl)piperidin-1-yl)sulfonyl)picolinoyl)glycine;Glycine, N-[[5-[[4-(4-chlorophenyl)-1-piperidinyl]sulfonyl]-2-pyridinyl]carbonyl]-
CAS No.2851040-81-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACZXFN647 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACZXFN647 route product structure diagram
    ACZXFN6472851040-81-6 In Stock
Inquiry

2. ACZXFN647 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACZXFN647 route product structure diagram
    ACZXFN6472851040-81-6 In Stock
Inquiry

Comments (0)